Citius Pharmaceuticals announced that the FDA has approved Lymphir, a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma after at least one prior systemic therapy. Lymphir is the only CTCL therapy that targets the interleukin-2 receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and the first FDA-approved product for Citius Pharma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- TenX Keane shareholders approve merger with Citius subsidiary
- TenX Keane shareholders approve merger with Citius Oncology
- Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
- Citius Pharmaceuticals initiated with a Buy at EF Hutton
- 2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect
Questions or Comments about the article? Write to editor@tipranks.com